West Paces Advisors’s Alaunos Therapeutics TCRT Stock Holding History

West Paces Advisors’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23	Buy	+10	New	+$26	﹤0.01%	763
2025 Q2	–	Sell	-10	Closed	-$15	–	515
2025 Q1	$15	Hold	10	–	–	﹤0.01%	563
2024 Q4	$19	Hold	10	–	–	﹤0.01%	556
2024 Q3	$32	Hold	10	–	–	﹤0.01%	546
2024 Q2	$70	Hold	10	–	–	﹤0.01%	562
2024 Q1	$181	Hold	10	–	–	﹤0.01%	573
2023 Q4	$106	Hold	10	–	–	﹤0.01%	603
2023 Q3	$198	Hold	10	–	–	﹤0.01%	511
2023 Q2	$765	Hold	10	–	–	﹤0.01%	503
2023 Q1	$945	Hold	10	–	–	﹤0.01%	512
2022 Q4	$974	Buy	+10	New	+$1.45K	﹤0.01%	479

Other funds holding TCRT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

AAP

Arax Advisory Partners Denver, Colorado $15.1B AUM 27.93% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

West Paces Advisors's TCRT Position: Q2 2026 in Review

West Paces Advisors opened a new position in Alaunos Therapeutics (TCRT) in Q2 2026: 10 shares worth $23. The stake represents ﹤0.01% of the portfolio and ranks #763 among its holdings. This is a return to the name: West Paces Advisors previously reported a position in TCRT as recently as Q1 2025.

West Paces Advisors first reported a position in TCRT in Q4 2022 and has held it in 11 quarters since. The position peaked at $974 in Q4 2022. 29 funds tracked by Wall St. Rank hold TCRT as of Q2 2026.

West Paces Advisors held 10 shares of Alaunos Therapeutics worth $23 as of Q2 2026.
Alaunos Therapeutics was a new West Paces Advisors position in Q2 2026.
Alaunos Therapeutics made up ﹤0.01% of West Paces Advisors's portfolio in Q2 2026, its #763 holding.
West Paces Advisors first reported a position in Alaunos Therapeutics in Q4 2022 and has held it in 11 quarters since.
West Paces Advisors's Alaunos Therapeutics position peaked at $974 in Q4 2022.
29 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2026.

Based on West Paces Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.